Aberdeen Group plc Purchases 286,335 Shares of Abivax SA Sponsored ADR $ABVX

Aberdeen Group plc grew its position in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 67.5% in the first quarter, Holdings Channel.com reports. The fund owned 710,516 shares of the company’s stock after buying an additional 286,335 shares during the period. Aberdeen Group plc’s holdings in Abivax were worth $4,441,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of ABVX. Two Sigma Investments LP acquired a new position in shares of Abivax in the fourth quarter valued at $144,000. GAMMA Investing LLC increased its holdings in Abivax by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company’s stock valued at $118,000 after buying an additional 14,855 shares during the period. Guggenheim Capital LLC acquired a new position in shares of Abivax in the 4th quarter valued at $92,000. BNP Paribas Financial Markets raised its stake in shares of Abivax by 47.5% in the 4th quarter. BNP Paribas Financial Markets now owns 19,244 shares of the company’s stock valued at $141,000 after buying an additional 6,200 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Abivax by 44.2% during the 4th quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock worth $6,816,000 after acquiring an additional 285,542 shares during the period. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ABVX. Piper Sandler upped their target price on shares of Abivax from $70.00 to $112.00 and gave the company an “overweight” rating in a research note on Tuesday, July 29th. Morgan Stanley raised Abivax from an “equal weight” rating to an “overweight” rating and set a $71.00 target price for the company in a report on Wednesday, July 23rd. Citigroup restated a “market outperform” rating on shares of Abivax in a research report on Friday, July 18th. JMP Securities boosted their target price on shares of Abivax from $33.00 to $95.00 and gave the company a “market outperform” rating in a research note on Wednesday, July 23rd. Finally, Guggenheim boosted their target price on Abivax from $50.00 to $101.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $92.33.

Abivax Price Performance

Shares of ABVX stock opened at $71.89 on Thursday. Abivax SA Sponsored ADR has a 1 year low of $4.77 and a 1 year high of $75.51. The company has a current ratio of 1.25, a quick ratio of 1.25 and a debt-to-equity ratio of 1.29. The firm’s 50 day moving average is $33.93 and its 200-day moving average is $16.06.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.